Candriam S.C.A. Has $20.85 Million Holdings in Edwards Lifesciences Corporation $EW

Candriam S.C.A. boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.8% in the 1st quarter, Holdings Channel.com reports. The firm owned 260,327 shares of the medical research company’s stock after buying an additional 25,359 shares during the quarter. Candriam S.C.A.’s holdings in Edwards Lifesciences were worth $20,847,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of EW. State Street Corp increased its holdings in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP lifted its stake in shares of Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after buying an additional 989,533 shares during the period. Norges Bank acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $803,686,000. Morgan Stanley raised its stake in shares of Edwards Lifesciences by 12.4% in the fourth quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after purchasing an additional 804,942 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Edwards Lifesciences by 66.1% in the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after purchasing an additional 2,359,128 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Up 1.0%

EW stock traded up $0.89 during trading on Friday, hitting $92.22. The company had a trading volume of 3,381,397 shares, compared to its average volume of 4,354,287. The firm has a 50-day moving average price of $86.73 and a 200-day moving average price of $83.87. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock has a market cap of $53.10 billion, a price-to-earnings ratio of 49.05, a PEG ratio of 2.31 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,577 shares of company stock worth $3,855,527 over the last 90 days. Insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on EW shares. Citigroup boosted their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Tuesday, June 16th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Evercore reiterated an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Finally, BTIG Research boosted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.09.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.